American Century Companies Inc. Raises Stock Position in Generation Bio Co. (NASDAQ:GBIO)

American Century Companies Inc. grew its holdings in Generation Bio Co. (NASDAQ:GBIO) by 199.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 31,786 shares of the company’s stock after purchasing an additional 21,167 shares during the quarter. American Century Companies Inc.’s holdings in Generation Bio were worth $90,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in GBIO. Price T Rowe Associates Inc. MD lifted its holdings in Generation Bio by 28.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,878,361 shares of the company’s stock worth $36,136,000 after buying an additional 1,952,187 shares in the last quarter. Baker BROS. Advisors LP acquired a new stake in shares of Generation Bio in the first quarter valued at $1,511,000. Acadian Asset Management LLC raised its stake in shares of Generation Bio by 113.9% in the first quarter. Acadian Asset Management LLC now owns 479,835 shares of the company’s stock valued at $1,952,000 after acquiring an additional 255,468 shares in the last quarter. Bellevue Group AG boosted its holdings in Generation Bio by 6.8% in the first quarter. Bellevue Group AG now owns 3,861,575 shares of the company’s stock valued at $15,717,000 after purchasing an additional 244,495 shares during the period. Finally, Yiheng Capital Management L.P. acquired a new position in Generation Bio during the 1st quarter worth $780,000. Institutional investors and hedge funds own 95.22% of the company’s stock.

Generation Bio Price Performance

NASDAQ:GBIO opened at $2.48 on Friday. Generation Bio Co. has a 12 month low of $0.86 and a 12 month high of $4.65. The firm has a market capitalization of $164.99 million, a PE ratio of -0.97 and a beta of 2.81. The business’s fifty day moving average price is $2.57 and its 200 day moving average price is $2.96.

Generation Bio (NASDAQ:GBIO) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Generation Bio had a negative net margin of 1,202.56% and a negative return on equity of 92.86%. The business had revenue of $4.09 million during the quarter, compared to analysts’ expectations of $3.23 million. As a group, equities analysts anticipate that Generation Bio Co. will post -1.8 EPS for the current year.

Analyst Ratings Changes

GBIO has been the topic of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $5.00 price target on shares of Generation Bio in a research report on Thursday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 target price on shares of Generation Bio in a report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Generation Bio has an average rating of “Hold” and a consensus target price of $7.50.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.